NASDAQ$OFIX

Orthofix Medical Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Orthofix reported first quarter results with net sales increasing and strategic initiatives showing promise

Orthofix reported a strong first quarter with a 65% increase in net sales to $175.2 million. The company saw growth across all channels, driven by cross-selling strategies and new product launches. However, the company reported a net loss of $(60.9) million, or $(1.71) per share and an adjusted net loss of $(3.6) million, or $(0.10) per share.

  • Net sales increased by 65% to $175.2 million, with a 12% increase on a pro forma constant currency basis.
  • Bone Growth Therapies grew by 14%, driven by both spine and fracture commercial channels.
  • U.S. spinal implant sales increased by 18% on a pro forma basis, due to new distribution and product innovation.
  • Global Orthopedics experienced continued double-digit growth on a constant currency basis.

Headline financials

Total Revenue

$175M

Previous: $106M+64.6%
EPS (adj)

-$0.10

Previous: -$0.10+0.0%
Capital Expenditures

-$11.5M

Previous: -$5.33M-115.3%
Free Cash Flow

-$72.4M

Previous: -$9.79M-639.7%
Net Income

-$60.9M

Previous: -$4.46M-1266.3%
Operating Income

-$59.7M

Previous: -$3.08M-1840.0%
Gross Profit

$110M

Previous: $78.1M+41.3%
Cash & Equivalents

$50M

Previous: $71.9M-30.5%
Total Assets

$917M

Previous: $462M+98.5%
Stock-Based Comp

$13M

Previous: $4.33M+200.6%

Revenue & EPS history

Orthofix · Revenue · Quarterly

$175M

Q1 2023+64.6%vs Q1 2022
Beat estimate in 10 of 14 quarters(71%)
ActualEstimate

Revenue by segment

Orthofix · $73.7M total across 2 segments · Q1 2023

  • Bone Growth Therapies
    $47.7M+13.7%
  • Global Limb Reconstruction
    $26M+9.4%

Forward guidance

The Company expects net sales for the year ended December 31, 2023 to be between $750 million and $756 million and adjusted EBITDA to be between $40 million and $45 million.

Tailwinds

  • Full year net sales are expected to be between $750 million and $756 million.
  • Represents a year-over-year increase of 62.8% to 64.1% on a reported basis
  • Represents an increase of 7.0% to 7.9% on a pro forma basis
  • Full year adjusted EBITDA is expected to be between $40 million and $45 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

-0.9%

Avg return

Earnings day

-2.6%

Avg return

5 days after

-3.4%

Avg return

30 days after

48%

31 / 65 earnings

Positive

+20.3%

Q2 2014

Best reaction

-18.5%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.8%-2.8%-13.8%
Q4 2025-7.0%-0.4%-13.2%
Q3 2025-7.4%-6.8%-1.0%
Q1 2025-10.8%-10.6%-20.9%
Q4 2024-3.5%-4.2%-11.0%
Q3 2024+5.5%+4.6%+1.2%
Q2 2024+13.8%+10.8%+16.7%
Q1 2024+10.7%+8.8%+0.6%
Q4 2023+8.1%+7.1%+8.6%
Q3 2023-12.5%-20.2%-3.2%
Q2 2023+9.9%+7.6%+1.3%
Q1 2023+1.0%-2.3%+6.7%
Q4 2022-7.7%-13.2%-15.5%
Q3 2022-2.2%+4.1%+30.5%
Q2 2022-6.6%-8.8%-20.9%
Q1 2022-10.5%-14.3%-11.6%
Q4 2021+4.0%+3.5%+0.4%
Q3 2021-5.9%-10.9%-18.6%
Q2 2021+8.9%+4.1%+12.4%
Q1 2021+0.5%-2.0%-8.7%
Q4 2020+0.6%-0.5%-7.3%
Q3 2020+5.2%+13.6%+10.8%
Q2 2020+4.5%+4.6%-13.4%
Q1 2020-1.9%-6.9%+3.9%
Q4 2019-18.5%-21.5%-40.9%
Q3 2019-16.8%-17.0%-9.6%
Q2 2019+0.1%+2.6%-5.5%
Q1 2019-2.6%-0.3%-10.9%
Q4 2018-8.5%-10.0%-14.8%
Q3 2018+7.4%+8.8%+4.1%
Q2 2018-15.1%-11.9%-12.1%
Q1 2018-13.4%-14.6%-10.5%
Q4 2017+6.4%+4.6%+8.4%
Q3 2017+8.8%+5.1%+9.6%
Q2 2017+9.9%+6.8%+12.3%
Q1 2017+1.4%+3.8%+8.2%
Q4 2016-6.1%-4.8%+2.6%
Q3 2016-3.8%-6.8%-1.5%
Q2 2016-10.4%-10.5%-4.8%
Q1 2016+0.4%
Q4 2015+2.8%
Q3 2015+14.4%
Q2 2015+13.8%
Q1 2015+0.4%
Q4 2014-10.8%
Q3 2014+20.3%
Q2 2014+20.3%
Q1 2014+4.2%
Q4 2013+14.1%
Q3 2013+1.1%
Q2 2013-0.8%
Q1 2013-16.4%
Q4 2012-4.9%
Q3 2012-2.8%
Q2 2012+4.5%
Q1 2011-0.7%
Q1 2012+1.0%
Q1 2010-4.8%
Q4 2011-4.8%
Q4 2009-4.8%
Q3 2010-7.4%
Q3 2011-7.4%
Q4 2010-9.5%
Q2 2010-9.5%
Q2 2011-9.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro